Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

939 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group.
Jukema JW, Zwinderman AH, van Boven AJ, Reiber JH, Van der Laarse A, Lie KI, Bruschke AV. Jukema JW, et al. Among authors: zwinderman ah. Arterioscler Thromb Vasc Biol. 1996 Mar;16(3):425-30. doi: 10.1161/01.atv.16.3.425. Arterioscler Thromb Vasc Biol. 1996. PMID: 8630669 Clinical Trial.
The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study.
Jukema JW, van Boven AJ, Groenemeijer B, Zwinderman AH, Reiber JH, Bruschke AV, Henneman JA, Molhoek GP, Bruin T, Jansen H, Gagné E, Hayden MR, Kastelein JJ. Jukema JW, et al. Among authors: zwinderman ah. Circulation. 1996 Oct 15;94(8):1913-8. doi: 10.1161/01.cir.94.8.1913. Circulation. 1996. PMID: 8873668 Clinical Trial.
Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group.
Cobbaert C, Jukema JW, Zwinderman AH, Withagen AJ, Lindemans J, Bruschke AV. Cobbaert C, et al. Among authors: zwinderman ah. J Am Coll Cardiol. 1997 Nov 15;30(6):1491-9. doi: 10.1016/s0735-1097(97)00353-7. J Am Coll Cardiol. 1997. PMID: 9362407 Free article. Clinical Trial.
-455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group.
de Maat MP, Kastelein JJ, Jukema JW, Zwinderman AH, Jansen H, Groenemeier B, Bruschke AV, Kluft C. de Maat MP, et al. Among authors: zwinderman ah. Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):265-71. doi: 10.1161/01.atv.18.2.265. Arterioscler Thromb Vasc Biol. 1998. PMID: 9484992 Review.
B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS).
de Groot E, Jukema JW, Montauban van Swijndregt AD, Zwinderman AH, Ackerstaff RG, van der Steen AF, Bom N, Lie KI, Bruschke AV. de Groot E, et al. Among authors: zwinderman ah. J Am Coll Cardiol. 1998 Jun;31(7):1561-7. doi: 10.1016/s0735-1097(98)00170-3. J Am Coll Cardiol. 1998. PMID: 9626835 Free article. Clinical Trial.
Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.
de Groot E, Jukema JW, van Boven AJ, Reiber JH, Zwinderman AH, Lie KI, Ackerstaff RA, Bruschke AV. de Groot E, et al. Among authors: zwinderman ah. Am J Cardiol. 1995 Sep 28;76(9):40C-46C. doi: 10.1016/s0002-9149(99)80469-x. Am J Cardiol. 1995. PMID: 7572685 Clinical Trial.
939 results